Advertisement

Langenbeck's Archives of Surgery

, Volume 389, Issue 4, pp 299–305 | Cite as

Cancer cachexia

  • Michael J. TisdaleEmail author
New Surgical Horizons

Abstract

Causative factors

Nutritional supplementation or pharmacological manipulation of appetite are unable to control the muscle atrophy seen in cancer cachexia. This suggests that tumour and/or host factors might be responsible for the depression in protein synthesis and the increase in protein degradation. An increased expression of the ubiquitin–proteasome proteolytic pathway is responsible for the increased degradation of myofibrillar proteins in skeletal muscle, and this may be due to tumour factors, such as proteolysis-inducing factor (PIF), or host factors such as tumour necrosis factor-α (TNF-α). In humans loss of adipose tissue is due to an increase in lipolysis rather than a decrease in synthesis, and this may be due to tumour factors such as lipid-mobilising factor (LMF) or TNF-α, both of which can increase cyclic AMP in adipocytes, leading to activation of hormone-sensitive lipase (HSL). Levels of mRNA for HSL are elevated twofold in adipose tissue of cancer patients, while there are no changes in lipoprotein lipase (LPL), involved in extraction of fatty acids from plasma lipoproteins for storage.

Treatment for cachexia

This has concentrated on increasing food intake, although that alone is unable to reverse the metabolic changes. Agents interfering with TNF-α have not been very successful to date, although more research is required in that area. The only agent tested clinically that is able to interfere with the action of PIF is eicosapentaenoic acid (EPA). EPA attenuates protein degradation in skeletal muscle by preventing the increased expression of the ubiquitin–proteasome pathway, but has no effect on protein synthesis. When used alone EPA prevents further wasting in cachectic patients, and, when it is combined with an energy- and protein-dense nutritional supplement, weight gain is seen, which is totally lean body mass. These results suggest that mechanistic studies into the causes of cancer cachexia will allow appropriate therapeutic intervention.

Keywords

Cancer cachexia Proteolysis-inducing factor Muscle wasting Eicosapentaenoic acid Cytokines 

References

  1. 1.
    De Wys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497PubMedGoogle Scholar
  2. 2.
    Monitto CL, Berkowitz D, Lee KM, Pin S, Li D, Breslow M (2001) Differential gene expression in a murine model of cancer cachexia. Am J Physiol 281:E289–E297Google Scholar
  3. 3.
    Persson C, Glimeluis B (2002) The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 22:3661–3668PubMedGoogle Scholar
  4. 4.
    De Wys WD (1972) Anorexia as a general effect of cancer. Cancer 45:2013–2019Google Scholar
  5. 5.
    Evans WK, Makuch R, Clamon GH, et al (1985) Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 45:3347–3353PubMedGoogle Scholar
  6. 6.
    Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152–154PubMedGoogle Scholar
  7. 7.
    Okusaka T, Okada S, Ishii H, Ikeda M, Kosakomoto H, Yoshimori M (1998) Prognosis of advanced pancreatic cancer patients with reference to calorie intake. Nutr Cancer 32:55–58PubMedGoogle Scholar
  8. 8.
    Fearon KCH (1992) The mechanism and treatment of weight loss in cancer. Proc Nutr Soc 51:251–265PubMedGoogle Scholar
  9. 9.
    Shaw JH, Wolfe RR (1987) Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 205:368–376PubMedGoogle Scholar
  10. 10.
    Yam D, Ben-Hur H, Fink A, Dgani R, Shani A, Eliraz A, Insker V, Berry EM (1994) Insulin and glucose status, tissue and plasma lipids in patients with tumours of the ovary or endometrium: possible dietary implications. Br J Cancer 70:1186–1187PubMedGoogle Scholar
  11. 11.
    Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin–proteasome pathway. N Engl J Med 335:1897–1905PubMedGoogle Scholar
  12. 12.
    Fearon KCH, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T (1998) Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 227:249–254CrossRefPubMedGoogle Scholar
  13. 13.
    Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, et al (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75:2077–2082PubMedGoogle Scholar
  14. 14.
    Yoshizawa F (2004) Regulation of protein synthesis by branched-chain amino acids in vivo. Biochem Biophys Res Commun 313:417–422CrossRefPubMedGoogle Scholar
  15. 15.
    Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, Fanelli FR, Doglietto GB, Baccino FM (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237:384–389CrossRefPubMedGoogle Scholar
  16. 16.
    Jagoe RT, Redfern CPF, Roberts RG, Gibson GJ, Goodship THJ (2002) Skeletal muscle mRNA levels for cathepsins B, but not components of the ubiquitin–proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin Sci 102:353–361CrossRefPubMedGoogle Scholar
  17. 17.
    Bodine SC, Latres E, Baumheuter S, et al (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708CrossRefPubMedGoogle Scholar
  18. 18.
    Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhum P (2004) Zinc-(2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 101:2500–2505CrossRefGoogle Scholar
  19. 19.
    Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58:2359–2365PubMedGoogle Scholar
  20. 20.
    Todorov PT, Caruik P, McDevitt T, Coles B, Fearon K, Tisdale M (1996) Characterization of a cancer cachectic factor. Nature 379:739–742PubMedGoogle Scholar
  21. 21.
    Watchorn TM, Waddell ID, Dowidar N, Ross JA (2001) Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-κB and STAT3. FASEB J 15:562–564PubMedGoogle Scholar
  22. 22.
    Maltoni M, Fabbri L, Nani O, Scarpi E, Pezzi L, Flamini E, Riccobon A, Derni S, Pallotti G, Amadori D (1997) Serum levels of tumour necrosis factor and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5:130–135PubMedGoogle Scholar
  23. 23.
    Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simppoulos K (2001) Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients. Anticancer Res 21:1355–1358PubMedGoogle Scholar
  24. 24.
    Sheen-Chen S-M, Chen W-J, Eng H-L, Chou F-F (1997) Serum concentrations of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43:211–215CrossRefPubMedGoogle Scholar
  25. 25.
    Shibata M, Takekawa M (1997) Increased serum concentrations of circulatory soluble receptors for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology 56:54–58CrossRefGoogle Scholar
  26. 26.
    Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KCH (2000) Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 87:53–58PubMedGoogle Scholar
  27. 27.
    Caruik P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ (1997) Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 76:606–613PubMedGoogle Scholar
  28. 28.
    Grunfeld C, Feingold KR (1991) Tumor necrosis factor, cytokines and hyperlipidemia of infection. Trends Endocrinol Metab 2:213–219Google Scholar
  29. 29.
    Strassman G, Kambayashi T (1995) Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine receptor therapy. Cytokines Mol Ther 1:107–113PubMedGoogle Scholar
  30. 30.
    Russell ST, Hirai K, Tisdale MJ (2002) Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86:424–428CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang HH, Halbleib M, Ahmad R et al (2002) Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and evaluation of intracellular cyclic AMP. Diabetes 51:2929–2935PubMedGoogle Scholar
  32. 32.
    Legaspi A, Jeevanandam M, Starnes HF, Brennan MF (1987) Whole-body lipid and energy metabolism in the cancer patient. Metabolism 36:958–963CrossRefPubMedGoogle Scholar
  33. 33.
    Thompson MP, Cooper ST, Parry BR, Tuckey JA (1993) Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochem Biophys Acta 1180:236–242CrossRefPubMedGoogle Scholar
  34. 34.
    Drott C, Perrson H, Lundholm K (1989) Cardiovascular and metabolic response to adrenaline infusion in weight-losing cancer patients with and without cancer. Clin Physiol 9:427–439PubMedGoogle Scholar
  35. 35.
    Melville S, McNurlan MA, Calder AG, Garlick PJ (1990) Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res 50:1125–1131PubMedGoogle Scholar
  36. 36.
    Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM (1993) Acute treatment with tumour necrosis factor-α induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 125:11–18PubMedGoogle Scholar
  37. 37.
    Lorite MJ, Cariuk P, Tisdale MJ (1997) Induction of muscle protein degradation by a tumour factor. Br J Cancer 76:1035–1040PubMedGoogle Scholar
  38. 38.
    Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ (2001) Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 85:297–302PubMedGoogle Scholar
  39. 39.
    Llovera M, Carbo N, Lopez-Soriano J, Garcia-Martinez C, Busquets S, Alvarez B et al (1998) Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 13:83–87CrossRefGoogle Scholar
  40. 40.
    Jentsch S, McGrath IP, Varshavsky A (1987) The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzyme. Nature 329:131–134PubMedGoogle Scholar
  41. 41.
    Glotzer M, Murray AW, Kirschner MN (1991) Cyclin is degraded by the ubiquitin pathway. Nature 349:132–138PubMedGoogle Scholar
  42. 42.
    Gomes-Marcondes MCC, Smith HJ, Cooper JC, Tisdale MJ (2002) Development of an in vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer 86:1628–1633CrossRefPubMedGoogle Scholar
  43. 43.
    Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB (1998) Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J 12:871–880PubMedGoogle Scholar
  44. 44.
    Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM (1997) TNF can directly induce the expression of the ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 230:238–244CrossRefPubMedGoogle Scholar
  45. 45.
    Whitehouse AS, Tisdale MJ (2003) Increased expression of the ubiquitin–proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB. Br J Cancer 89:1116–1122CrossRefPubMedGoogle Scholar
  46. 46.
    Li Y-P, Reid MB (2000) NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol 279:R1165–R1170Google Scholar
  47. 47.
    Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM (1994) Interleukin-6 does not activate protein breakdown in rat skeletal muscle. Cancer Lett 76 1–4Google Scholar
  48. 48.
    Goodman MN (1994) Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205:182–185PubMedGoogle Scholar
  49. 49.
    Espat NJ, Auffenberg T, Rosenberg JJ, Martin RD, Fang CH, Hasselgren P-O, Copeland EM, Moldawer LL (1996) Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol 271:R185–R190PubMedGoogle Scholar
  50. 50.
    Fujita J, Tsujinaka T, Yano M, et al (1996) Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 68:637–643CrossRefPubMedGoogle Scholar
  51. 51.
    Baracos V, Rodeman HP, Dinarello CA, Goldberg AL (1983) Stimulation of muscle protein degradation and prostaglandin E2 release by leukocyte pyrogen (interleukin-1). N Engl J Med 308:553–555PubMedGoogle Scholar
  52. 52.
    Goldberg AL, Kettlehut IC, Foruno K, Fagan JM, Baracos V (1988) Activation of protein breakdown and prostaglandin E2 production in rat skeletal muscle in fever is signaled by a microphage product distinct from interleukin-1 or other known monokines. J Clin Invest 81:1378–1383PubMedGoogle Scholar
  53. 53.
    Ling PK, Istfan N, Blackburn GL, Bistrian BR (1991) Effects of interleukin 1-β (IL-1) and combination of IL-1 and tumor necrosis factor on tumor growth and protein metabolism. J Nutr Biochem 2:553–559CrossRefGoogle Scholar
  54. 54.
    Bishop JF, Smith JG, Jeal PN, Murray R, Drummond RM, Pitt P, Olver IN, Bhowal AK (1993) The effect of danzol on tumour control and weight loss in patients on tamoxifen for advanced breast cancer: a randomised double-blind placebo controlled trial. Eur J Cancer 29A:814–818PubMedGoogle Scholar
  55. 55.
    Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662PubMedGoogle Scholar
  56. 56.
    Lundholm K, Gelin J, Hyltander A, et al (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumours. Cancer Res 54:5602–5606PubMedGoogle Scholar
  57. 57.
    Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, Fearon KCH (1995) Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 72:185–188PubMedGoogle Scholar
  58. 58.
    McMillan DC, Wigmore SJ, Fearon KCH, O’Gorman P, Wright CE, McArdle CS (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79:495–500CrossRefPubMedGoogle Scholar
  59. 59.
    Goldberg RM, Loprinzi CL, Malliard JA et al (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13:2856–2859PubMedGoogle Scholar
  60. 60.
    Reyo-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled trial. AIDS 10:1501–1507PubMedGoogle Scholar
  61. 61.
    Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, Zubelewicz B, Chatikhine V (1996) Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A:1340–1343CrossRefPubMedGoogle Scholar
  62. 62.
    Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001) Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61:3604–3609PubMedGoogle Scholar
  63. 63.
    Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KCH (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12:S27–S30PubMedGoogle Scholar
  64. 64.
    Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177–184PubMedGoogle Scholar
  65. 65.
    Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86PubMedGoogle Scholar
  66. 66.
    Barber MD, Fearon KCH, Tisdale MJ, McMillan DC, Ross JA (2001) Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 40:118–124CrossRefPubMedGoogle Scholar
  67. 67.
    Fearon KCH, von Megenfeldt MF, Moses AGW et al (2003) Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Pharmaceutical Sciences Research InstituteAston UniversityBirminghamUK

Personalised recommendations